Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies

The nucleoside analogue decitabine can deplete the epigenetic regulator DNA methyltransferase 1 (DNMT1), an effect that occurs, and is saturated at, low concentrations/doses. A reason to pursue this molecular‐targeted effect instead of the DNA damage/cytotoxicity produced with high concentrations/do...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Haematol
Prif Awduron: Awada, Hassan, Mahfouz, Reda Z., Kishtagari, Ashwin, Kuzmanovic, Teodora, Durrani, Jibran, Kerr, Cassandra M., Patel, Bhumika J., Visconte, Valeria, Radivoyevitch, Tomas, Lichtin, Alan, Carraway, Hetty E., Maciejewski, Jaroslaw P., Saunthararajah, Yogen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Haematological Malignancy – Clinical
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7154732/
https://ncbi.nlm.nih.gov/pubmed/31736067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16281
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg